Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS ‘Safe Harbor’ For Use Of Copay Accumulators In Private Insurance Challenged In Court

Executive Summary

Patient groups ‘left with no choice’ but to challenge federal regulation allowing commercial payers to bar manufacturer assistance with drug costs from being counted toward deductibles and out-of-pocket spending caps.

You may also be interested in...



Copay Accumulators: Pending CMS Reg May Offer More Clarity After Judge Limits Scope

Programs only allowed for brands with generic competition under court ruling, but related programs such as copay maximizers and so-called ‘alternative funding’ programs are not directly impacted by the decision.

Specialty Drug ‘Doom Loop:’ Manufacturers Fight Against Becoming Primary Payers For Own Drugs

Drug Channels’ Adam Fein described the ongoing and escalating battle between manufacturers and payers over the cost of specialty drugs during a recent webinar.

Generic Tiering Requirement, Enhanced Oversight On Chronic Meds Proposed For Marketplace Plans

Commercial health insurance plans governed by the Affordable Care Act would need to modify their formularies for 2024 with policies to avoid discriminatory coverage of four ‘chronic ... high-cost medical conditions’ as well as overpayment for generics, according to CMS proposals.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS146932

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel